Advanced Filter

Filter by Group

Filter by Market Availability

Displaying all 6 drugs
Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to aripiprazole, brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared...
Approved
Investigational
Matched Synonyms: … Brexpiprazole
Matched Name: … Brexpiprazole
Matched Description: … [A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. ... Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called ... Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects …
Matched Salts name: … Brexpiprazole dihydrochloride …
Matched Categories: … brexpiprazole
Matched Products: … Brexpiprazole ... REXULTI (BREXPIPRAZOLE) TABLETS 1 MG ... REXULTI (BREXPIPRAZOLE) TABLETS 2 MG …
Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including aripiprazole, paliperidone and clozapine available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the...
Approved
Investigational
Matched Description: … [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or
OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical.
Investigational
Matched Name: … OPC-14523 …
Matched Description: … OPC-14523 is an antidepressant drug developed by Otsuka America Pharmaceutical. …
Matched Salts name: … OPC-14523 mesylate ... OPC-14523 hydrochloride …
OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. It is a V(2)-selective agonist that produces a significant antidiuretic action after single and multiple oral dosing in AVP-deficient and normal AVP states. It is useful therapeutic drug in the treatment of hypothalamic diabetes insipidus, nocturnal enuresis, and some kinds of...
Investigational
Matched Name: … OPC-51803 …
Matched Description: … OPC-51803 is the first nonpeptide vasopressin (AVP) V(2)-receptor-selective agonist. …
At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action at alpha-2-adrenoceptors while having minimal action on systemic blood pressure, heart rate and coronary, carotid, vertebral, renal, and mesenteric blood flows. It is the only clinical compound with this profile. It is currently being...
Investigational
Matched Name: … OPC-28326 …
Matched Description: … At low doses, OPC 28326 selectively vasodilates the femoral arterial bed due to its inhibitory action …
OPC1 is an oligodendrocyte progenitor cell therapy being investigated for the treatment of acute spinal cord injury.
Investigational
Displaying all 6 drugs